Published in J Acquir Immune Defic Syndr on February 01, 2004
Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis (2008) 1.30
Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev (2009) 1.17
Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci (2007) 1.10
Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol (2011) 1.08
Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis (2005) 1.07
Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients. Brain Imaging Behav (2010) 1.01
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr (2013) 0.93
The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. J Int Neuropsychol Soc (2009) 0.92
Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals. Curr Opin Investig Drugs (2010) 0.91
Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection. J Acquir Immune Defic Syndr (2013) 0.91
Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. AIDS Care (2011) 0.82
Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances. Neurobehav HIV Med (2012) 0.80
The impact of human immune deficiency virus and hepatitis C coinfection on white matter microstructural integrity. J Neurovirol (2015) 0.77
Experiences of Oxford House Residents Living with the Hepatitis C Virus. Front Psychol Behav Sci (2013) 0.75
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. J Neurovirol (2016) 0.75
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Lyme borreliosis. Lancet Infect Dis (2003) 4.58
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res (2003) 2.37
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
[A 64-year old woman with otitis media, splenic infarction and pareses]. Tidsskr Nor Laegeforen (2008) 1.38
Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther (2006) 1.37
Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics (2005) 1.27
Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease. J Neurol (2005) 1.17
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int (2006) 1.16
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure. J Clin Virol (2009) 1.06
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother (2007) 1.06
Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology (2002) 1.05
AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood (2005) 1.00
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler (2010) 0.98
HIV Dementia Scale and psychomotor slowing--the best methods in screening for neuro-AIDS. J Neuropsychiatry Clin Neurosci (2005) 0.97
Cyclic AMP and tumor necrosis factor-alpha regulate CXCR4 gene expression in Schwann cells. Mol Cell Neurosci (2003) 0.95
Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurol (2012) 0.91
Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol (2005) 0.88
SEN virus infection. Rev Med Virol (2004) 0.88
Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C. Dig Dis Sci (2002) 0.88
Subclinical reactivation of varicella zoster virus in all stages of HIV infection. J Neurol Sci (2011) 0.88
Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol (2003) 0.88
Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Med Microbiol Immunol (2010) 0.88
Risk factors associated with older age in treatment-naive HIV-positive patients. Intervirology (2012) 0.87
Human immunodeficiency virus 1-associated minor motor disorders: perfusion-weighted MR imaging and H MR spectroscopy. Radiology (2003) 0.86
Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol (2014) 0.85
CD8 T-cell subsets and viral load in the cerebrospinal fluid of therapy-naive HIV-infected individuals. AIDS (2007) 0.84
Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. J Vis Exp (2011) 0.84
Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials (2003) 0.83
Late-stage neurosyphilis presenting with severe neuropsychiatric deficits: diagnosis, therapy, and course of three patients. J Neurol (2011) 0.83
Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol (2006) 0.82
Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array. J Neurovirol (2009) 0.82
Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr (2002) 0.82
Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies. J Gen Virol (2003) 0.81
Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety. Eur J Med Res (2005) 0.80
Functional CXCR4 receptor development parallels sensitivity to HIV-1 gp120 in cultured rat astroglial cells but not in cultured rat cortical neurons. J Neurovirol (2002) 0.80
Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy. J Neurol (2008) 0.80
Cytokine levels in CSF and neuropsychological performance in HIV patients. J Neurovirol (2012) 0.80
Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res Hum Retroviruses (2003) 0.80
Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Liver Int (2007) 0.80
Endogenous or exogenous spreading of HIV-1 in Nordrhein-Westfalen, Germany, investigated by phylodynamic analysis of the RESINA Study cohort. Med Microbiol Immunol (2012) 0.80
Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase. J Virol Methods (2002) 0.78
Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin. Hepatology (2008) 0.78
SEN virus has an adverse effect on the survival of HIV-positive patients. AIDS (2005) 0.78
Proviral DNA as a Target for HIV-1 Resistance Analysis. Intervirology (2015) 0.78
HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany. Med Microbiol Immunol (2011) 0.78
Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals. J Neural Transm (Vienna) (2013) 0.78
Disturbance of cultured rat neuronal network activity depends on concentration and ratio of leucine and alpha-ketoisocaproate: implication for acute encephalopathy of maple syrup urine disease. Pediatr Res (2003) 0.77
Budesonide-induced acute hepatitis in an HIV-positive patient with ritonavir as a co-medication. AIDS (2002) 0.77
Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis. BMJ Case Rep (2012) 0.77
TMC-125 Tibotec. Curr Opin Investig Drugs (2004) 0.77
Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort. J Med Virol (2011) 0.76
Persistent organic personality change as rare psychiatric manifestation of MELAS syndrome. J Neurol (2003) 0.76
SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration. World J Gastroenterol (2004) 0.76
Severe aseptic leucoencephalopathy as immune reconstitution inflammatory syndrome in Caucasian and African patients. AIDS (2009) 0.76
Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease. J Neurovirol (2004) 0.75
[Update HIV and neurology]. Dtsch Med Wochenschr (2015) 0.75
Proceedings of the 10th International Conference on Neuroscience of HIV Infection: emerging issues. J Neurovirol (2002) 0.75
A 69-year-old man with left hemispheric necrotizing mass lesion. Brain Pathol (2009) 0.75
Drug treatment for HIV-1-associated dementia. Curr Opin Investig Drugs (2002) 0.75
Fecal microbiota transplantation for Clostridium difficile-associated colitis in a severely immunocompromized critically ill AIDS patient: a case report. AIDS (2014) 0.75
Acute axonal neuropathy and Wernicke's encephalopathy. J Neurol (2006) 0.75
HIV-Associated Gastrointestinal Cancer. Oncol Res Treat (2017) 0.75
Cerebral malaria in spite of peripheral parasite clearance in a patient treated with atovaquone/proguanil. Parasitol Res (2006) 0.75
[Knotty skin tumors of an 80-year-old patient presenting with estimated diagnosis of chronic venous insufficiency]. Med Klin (Munich) (2005) 0.75
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. Int J Cancer (2017) 0.75
Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. Dig Dis Sci (2003) 0.75
HIV-Associated Anal Dysplasia and Anal Carcinoma. Oncol Res Treat (2017) 0.75
SEN virus seroprevalence in HIV positive patients: association with immunosuppression and HIV-replication. J Clin Virol (2004) 0.75
[Update hepatitis D]. Med Klin (Munich) (2006) 0.75
Central and peripheral nervous system functions are independently disturbed in HIV-1 infected patients. J Neurol (2002) 0.75